10-Q · May 14, 2026
Benitec Biopharma did not report any revenue for Q3 2026, yet achieved an improved net loss of $11.9 million, translating to an EPS of $(0.24). This shows a notable recovery from a $14.5 million loss and $(0.38) EPS for…
Earnings analysis · 10-K
BNTC earnings analysis
Filed September 14, 2026 · Our reading of the company's report
The latest report
Benitec enters FY2027 with substantially improved liquidity and meaningful BB-301 clinical progress, including completion of Cohort 1 follow-up and treatment of three Cohort 2 subjects. However, it remains a…
Read full summary
Benitec enters FY2027 with substantially improved liquidity and meaningful BB-301 clinical progress, including completion of Cohort 1 follow-up and treatment of three Cohort 2 subjects. However, it remains a single-asset, pre-revenue biotechnology company: FY2026 revenue was $0, net loss was $45.546 million, and R&D and G&A expenses totaled $51.192 million. The strategy and IP position are differentiated, but pivotal-study execution, third-party manufacturing, regulatory timing, and future equity financing remain decisive risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.98
- Segment
- Single reportable segment: discovery and development of therapeutic agents for genetic disorders; FY2026 operating expenses were $23.388 million in R&D and $27.804 million in G&A.
What stood out
-
Differentiated OPMD Gene-Therapy Platform
BB-301 is the company’s lead AAV9-based “silence and replace” therapy for OPMD, designed to permanently silence mutant PABPN1 while delivering a functional replacement gene in a single administration. The company states that no therapeutic agents are approved for OPMD and estimates the commercial opportunity exceeds $1 billion over the product’s commercial life. (10-K, Item 1)
-
BB-301 Clinical Program Progress
Clinical execution advanced: all Cohort 1 subjects safely completed the 12-month post-treatment follow-up period, and three subjects had been treated in Cohort 2. The FDA also held a Type C meeting during the third quarter of calendar 2026 regarding the BB-301 pivotal-study design. (10-K, Item 1)
-
Strongest-Ever Cash Position
Liquidity improved materially after financing activity: cash and cash equivalents were $179.972 million at June 30, 2026 versus $97.744 million a year earlier, while financing activities provided $98.977 million. Management estimates that cash will fund operations for at least the next twelve months. (10-K, Item 7 and Note 4)
-
Lower Operating Cash Burn
Operating cash burn improved to $16.518 million in FY2026 from $23.588 million in FY2025, although this improvement was accompanied by continued losses. The company invested only $0.105 million in property and equipment, indicating a capital-light operating model. (10-K, Item 7)
-
Broadening BB-301 IP Estate
The company expanded its patent coverage around BB-301, including four active OPMD patent families covering shmiRs, the silence-and-replace construct, the AAV9 vector, and proprietary administration devices and methods. A fifth OPMD family entered the national/regional phase in December 2025/January 2026. (10-K, Item 1)
-
Unlevered Balance Sheet
The company has no debt or credit facility and has never paid dividends. It raised $104.5 million of gross proceeds from common-stock issuance in FY2026, net of $6.266 million of issuance costs, preserving financial flexibility but increasing dependence on equity markets. (10-K, Item 7 and Note 9)
What to watch
-
Recent Restatement and Control Risk
A previously reported material weakness in share-based-compensation controls required remediation, and the company had restated interim financial statements for the quarters ended March 31, 2025 and December 31, 2024. Although management concluded the weakness was remediated as of December 31, 2025, FY2026 share-based compensation expense increased to $26.410 million from $17.426 million, leaving continued control-execution and reporting risk. (10-K, Items 1A and 9A; Note 9)
-
FDA Staffing and Policy Uncertainty
The filing identifies current U.S. administration workforce reductions and departures of experienced FDA personnel, stating that staffing and policy changes could delay or complicate regulatory submissions. BB-301 remains pre-approval, so a delay in the pivotal-study or BLA pathway could materially extend development timelines. (10-K, Item 1A)
-
Unsecured Long-Term Manufacturing Supply
Benitec does not own manufacturing facilities, relies entirely on third parties for BB-301 manufacturing, and has no long-term agreement with a third-party manufacturer. The filing states that manufacturing changes, supply interruptions, or failure to meet cGMP requirements could delay clinical trials or prevent commercialization. (10-K, Item 1)
Management's outlook
No numeric revenue or EPS guidance was provided in the 10-K. Management states that cash and cash equivalents are expected to fund operations for at least the next twelve months; the filing also notes that an FDA Type C meeting on BB-301 pivotal-study design occurred in Q3 2026.
Earlier filings 4
10-Q · February 12, 2026
Benitec Biopharma reported no revenue and a continuing net loss for the quarter: net loss of $11,837 thousand (three months ended Dec 31, 2025) and diluted EPS of $(0.26). The company materially strengthened its cash…
10-K · September 22, 2025
Benitec Biopharma is a clinical‑stage company advancing a first‑in‑class ddRNAi “silence and replace” AAV gene therapy (BB‑301) for OPMD. The filing highlights clinical progress (IND cleared June 2023; sixth subject…
10-Q · February 13, 2024
Benitec Biopharma reported zero revenue for the quarter (Licensing revenues $—) and a net loss of $ (6,798) (three months ended December 31, 2023), equivalent to reported EPS of $(2.64). R&D spend rose to $5,102 for the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.